Krystal Biotech Inc (KRYS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Krystal Biotech Inc   (NASDAQ: KRYS)


Krystal Biotech Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Krystal Biotech Inc's ROI in the second quarter of 2026?
Krystal Biotech Inc achieved a return on average invested assets (ROI) of 19.16 % in its second quarter of 2026, this is above KRYS's average return on investment of -5.7%.
Krystal Biotech Inc invested over the 12 months ending in its second quarter of 2026 $1,261 million

Despite the deterioration in its net income, company has improved ROI compared to the first quarter of 2026.

Within the Healthcare sector 60 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 342 to 344.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 29.51 % 28.01 % 26.53 % 24.61 % 21.68 %
Y / Y Net Income Change TTM 64.57 % 81.53 % 132.16 % 365.31 % 842.48 %
Investment (TTM) in Millions 1,373 1,289 1,231 1,149 1,051
Return On Investment (TTM) 19.16 % 19.07 % 18.51 % 19.18 % 15.08 %
KRYS's Overall Ranking # 344 # 342 # 246 # 118 # 396
Seq. Investment Change TTM 6.82 % 6.65 % 6.68 % 6.58 % 5.58 %
Seq. Net Income Change TTM 7.3 % 9.86 % 2.98 % 35.57 % 18.36 %
Net Income (TTM) in Millions 241 225 205 199 147

KRYS Company Profile >> Back to KRYS Roi Comparisons >> See Annual KRYS Return On Investment



Return On Investment KRYS's Ranking
Within: No.
Industry # 11
Sector # 61
Overall # 344

Return On Investment Statistics
High Average Low
19.18 %
-5.7 %
-25.44 %
(Sep 30 2025)   (Dec 31 2022)







Financial Statements
Krystal Biotech Inc's II. Quarter Investments $ 1,373 Millions KRYS's Balance sheet
Krystal Biotech Inc's II. Quarter Income $ 55 Millions Quarterly KRYS's Income Statement
KRYS's Income by Division See KRYS's Income by Division


KRYS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2021		 (Dec 31 2020)
2020
Total Investments in Millions 1,231 954 785 530 296
Y / Y Investment Growth 29.04 % 21.47 % 48.27 % 78.67 % 44.1 %
Net Income in Millions 205 89 11 -140 -32
Y / Y Net Income Growth 129.74 % 715.58 % - - -
Annual Return On Investment 16.64 % 9.35 % 1.39 % -26.43 % -10.85 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 16.64 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
KRYS's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for KRYS's Competitors
Subscribers only: Roi for Krystal Biotech Inc's Suppliers
Subscribers only: Return On Investment for KRYS's Customers

Other Ratios
KRYS's Roa KRYS's Inventory Turnover Ratio KRYS's Growth Rates KRYS's Dividend Statistics
KRYS's Profitability Ratios KRYS's Asset Turnover Ratio KRYS's Dividend Growth
KRYS's Roe KRYS's Valuation Ratios KRYS's Financial Strength Ratios KRYS's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %

Date modified: 2026-09-12T18:37:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.